Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review

Zhang, Shan; Tang, Sha; Li, Sheng; Pan, Yunlei; Ding, Yongsheng

doi:10.1080/09546634.2019.1577548

Cited by 54 publications

(38 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Excitingly, TNF-α antagonists are translated into clinical therapeutics for SJS/TEN in recent years. Tons of evidence supports TNF antagonists halt SJS/TEN ( Paradisi et al, 2014 ; Gavigan et al, 2018 ; Shear et al, 2018 ; Trujillo-Trujillo et al, 2018 ; Chafranska et al, 2019 ; Coulombe et al, 2019 ; Pham et al, 2019 ; Zhang et al, 2020 ). A randomized controlled trial compared etanercept (a TNF inhibitor) with systemic corticosteroid treatment in adult SJS/TEN patients and showed a decreased SCORTEN-predicted mortality rate, reduced skin healing time, and less gastrointestinal hemorrhage in the etanercept group.…”

Section: T-cell-mediated Apoptosis Signaling Pathways In Sjs/tenmentioning

confidence: 99%

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Cheng

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Adverse drug reactions are a public health issue that draws widespread attention, especially for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) which have high mortality and lack of efficacious treatment. Though T-cell-mediated HLA-interacted immune response has been extensively studied, our understanding of the mechanism is far from satisfactory. This review summarizes infection (virus, bacterial, and mycoplasma infection), an environmental risk factor, as a trigger for SJS/TEN. The mutations or polymorphisms of drug metabolic enzymes, transporters, receptors, the immune system genes, and T-cell-mediated apoptosis signaling pathways that contribute to SJS/TEN are discussed and summarized. Epigenetics, metabolites, and mobilization of regulatory T cells and tolerogenic myeloid precursors are emerged directions to study SJS/TEN. Ex vivo lymphocyte transformation test has been exploited to aid in identifying the causative drugs. Critical questions on the pathogenesis of SJS/TEN underlying gene polymorphisms and T cell cytotoxicity remain: why some of the patients carrying the risky genes tolerate the drug and do not develop SJS/TEN? What makes the skin and mucous membrane so special to be targeted? Do they relate to skin/mucous expression of transporters? What is the common machinery underlying different HLA-B alleles associated with SJS/TEN and common metabolites?

show abstract

Section: T-cell-mediated Apoptosis Signaling Pathways In Sjs/tenmentioning

confidence: 99%

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Cheng

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Concerning skin diseases, occasionally self‐limited skin allergies are treated with biologics. Namely, severe cases of drug‐induced exanthema such as toxic epidermal necrolysis might be treated with a single injection of anti‐TNF‐α as early at onset as possible . However, allergic skin rashes such as allergic contact dermatitis (ACD) or drug exanthema are self‐limited as soon as the trigger is removed and are usually not treated with biologics.…”

Section: Definition Of Skin Allergiesmentioning

confidence: 99%

New biological treatments for asthma and skin allergies

Eyerich

Metz

Bossios

et al. 2019

Allergy

View full text Add to dashboard Cite

Allergies are typically endemic, complex and heterogeneous diseases with a high impact at quality of life. Mechanistically, type 2 immune responses involving eosinophil and basophil granulocytes, mast cells and humoral factors such as IgE are key drivers of allergic diseases. Fighting allergic diseases knows three strategies: prevention, symptomatic and causative therapy. While remarkable progress was made in understanding molecular events in allergies as a prerequisite for effective prevention and desensitization, this review article focuses on the most efficient symptomatic treatments—that is using more and more specific antibodies neutralizing particular immune pathways. We highlight and classify recent and upcoming developments in the three prototype chronic allergic diseases allergic asthma, chronic spontaneous urticaria and atopic eczema. In all three examples, biologics such as dupilumab or omalizumab become reliable and efficient therapeutic options. Finally, we give an outlook how a diagnostic and therapeutic workflow might look like in the near future for these three major burdens of society.

show abstract

“…Nowadays the pharmacological inhibitors of TNFα and its receptors are developed ( Fig. 1, Panel A) and used in experiments as well as in clinical practice [46][47][48][49]. Pharmacological TNF-α inhibitors Infliximab (Remicade), Adalimubab (Humira), Certolizumab (Cimzia) and Golimumab (Simponi) are antibodies designed to TNF-α, whereas Etanercept (Enbrel) are antibodies designed to TNFRs [50][51][52].…”

Section: Inhibition Of Tnf-α Effectsmentioning

confidence: 99%

“…Pharmacological TNF-α inhibitors Infliximab (Remicade), Adalimubab (Humira), Certolizumab (Cimzia) and Golimumab (Simponi) are antibodies designed to TNF-α, whereas Etanercept (Enbrel) are antibodies designed to TNFRs [50][51][52]. Interestingly, the activation of sphingomyelinase in sphingomyelin hydrolysis leads to the formation of ceramides, galactosylceramides, and sulphatides in neurodegenerative brain diseases [46,49]. However, treatment with the antihistaminic agent dimebon -3,6-dimethyl-9-(2-methyl-pyrydyle-5)ethyl-1,2,3,4-tetrahydrocarboline dihydrochloride simultaneously with a blockade of H1 receptors were shown to suppress the activity of TNF-α, resulting in the prevention of Alzheimer's disease [53,54].…”

Section: Inhibition Of Tnf-α Effectsmentioning

confidence: 99%

Tumor Necrosis Factor Alpha: Role in the Development of Obesity and Diabetes Mellitus

Shamansurova

Saatov

Takhirov

2020

AJBGMB

View full text Add to dashboard Cite

Obesity and Diabetes Mellitus (DM) are defined as worldwide pandemics by the World health organization due to their economic burden and widespread. Although a huge amount of research is being done in the field of obesity and DM today, many questions remain unsolved. Tissue inflammation is the main factor in the development of both obesity and DM, leading towards irreversible changes in the tissue and formation of specific complications. One of the widespread cytokines, tumor necrosis factor alpha (TNF-α), was shown to be involved with inflammation in the development of metabolic disorders and neurodegenerative diseases. Even though the role of TNF-α in the pathogenesis of these two diseases remains unclear, new ways of treating and preventing diseases based on TNF-α antagonism attracted the attention of scientists. In this review, TNF-α and its receptors’ structures and properties are explored, and their role in disease development, including obesity and type 2 DM (DM2) will be discussed by viewing data from literature.

show abstract

Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review

Cited by 54 publications

References 33 publications

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

New biological treatments for asthma and skin allergies

Tumor Necrosis Factor Alpha: Role in the Development of Obesity and Diabetes Mellitus

Contact Info

Product

Resources

About